Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions

Benjamin T. Fitzgerald, Steven Lawrence Cohn, Allan L. Klein

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

Original languageEnglish
JournalCleveland Clinic Journal of Medicine
Volume72
Issue numberSUPPL.1
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Atrial Fibrillation
Stroke
Warfarin
Standard of Care
Anticoagulants
Aspirin
Direction compound
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stroke prevention in atrial fibrillation : Current anticoagulation management and future directions. / Fitzgerald, Benjamin T.; Lawrence Cohn, Steven; Klein, Allan L.

In: Cleveland Clinic Journal of Medicine, Vol. 72, No. SUPPL.1, 2004.

Research output: Contribution to journalArticle

Fitzgerald, Benjamin T. ; Lawrence Cohn, Steven ; Klein, Allan L. / Stroke prevention in atrial fibrillation : Current anticoagulation management and future directions. In: Cleveland Clinic Journal of Medicine. 2004 ; Vol. 72, No. SUPPL.1.
@article{b71fdf7dc85441c0b6c8c95b463969a3,
title = "Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions",
abstract = "Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.",
author = "Fitzgerald, {Benjamin T.} and {Lawrence Cohn}, Steven and Klein, {Allan L.}",
year = "2004",
doi = "10.3949/ccjm.72.Suppl_1.S24",
language = "English",
volume = "72",
journal = "Cleveland Clinic Journal of Medicine",
issn = "0891-1150",
publisher = "Cleveland Clinic Educational Foundation",
number = "SUPPL.1",

}

TY - JOUR

T1 - Stroke prevention in atrial fibrillation

T2 - Current anticoagulation management and future directions

AU - Fitzgerald, Benjamin T.

AU - Lawrence Cohn, Steven

AU - Klein, Allan L.

PY - 2004

Y1 - 2004

N2 - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

AB - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

UR - http://www.scopus.com/inward/record.url?scp=84884549179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884549179&partnerID=8YFLogxK

U2 - 10.3949/ccjm.72.Suppl_1.S24

DO - 10.3949/ccjm.72.Suppl_1.S24

M3 - Article

AN - SCOPUS:84884549179

VL - 72

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

SN - 0891-1150

IS - SUPPL.1

ER -